Bionic glomerular multistage sorting membrane and application thereof in continuous blood purification

Abstract

The invention relates to a bionic glomerular multistage sorting membrane and application thereof in continuous blood purification (CBP), and belongs to the technical field of biomedical engineering and blood purification. According to the membrane, the filtration mechanism of natural glomerulus is simulated, gradient aperture design and charge selective modification are adopted, efficient sorting is achieved, small molecules (such as urea and creatinine), middle molecules (such as beta2-microglobulin and inflammatory factors) and macromolecular toxins (such as protein binding toxins) can be removed at the same time, and meanwhile abnormal loss of albumin is greatly reduced. A traditional blood purification membrane is generally poor in treatment effect on solutes with different sizes and properties due to lack of a multi-stage sorting function, and especially has significant insufficiency in the aspect of albumin retention, so that the risks of hypoproteinemia and malnutrition of patients are increased. The bionic sorting membrane is closer to natural glomerulus in structure and function, the sorting and selective barrier characteristics are optimized, the bionic sorting membrane is particularly suitable for advanced blood purification systems such as CRRT and high interception hemodialysis (HCO-HD), an innovative extracorporeal circulation treatment solution is provided for critical patients, and the application prospect is wide. And the safety and the effect of overall treatment are improved.

Description

Technical Field

[0001] The present invention belongs to the technical fields of biomedical engineering and blood purification technology, and particularly relates to a bionic glomerular multi-stage sorting membrane and its application in continuous blood purification (CBP). By simulating the filtration mechanism of natural glomeruli, an artificial sorting membrane with a gradient pore size distribution and charge selectivity is designed to address key issues such as insufficient toxin clearance efficiency and albumin loss in existing blood purification technologies. Blood purification is an important means for treating diseases such as acute and chronic renal failure, sepsis, and multiple organ dysfunction syndrome (MODS), mainly including hemodialysis (HD), hemofiltration (HF), hemoperfusion (HP), and continuous renal replacement therapy (CRRT). The core of these technologies relies on the molecular sieving effect of semi-permeable membrane materials. However, traditional membranes (such as polysulfone, polyacrylonitrile, and cellulose-based) usually adopt a single pore size design and can only remove solutes within a specific molecular weight range, making it difficult to efficiently remove small molecules (such as urea and creatinine), medium molecules (such as β2-microglobulin and inflammatory factors), and large molecular toxins (such as protein-bound toxins) simultaneously. In addition, due to the lack of a charge-selective barrier similar to that of glomeruli, traditional membranes are prone to abnormal loss of albumin (~66 kDa) during filtration, increasing the risk of hypoproteinemia and malnutrition in patients.

[0002] The bionic glomerular multi-stage sorting membrane proposed by the present invention achieves a high sorting performance closer to that of natural glomeruli through structural bionics (gradient pore size) and functional bionics (charge modification), and can be widely applied to advanced blood purification systems such as CRRT and high cut-off hemodialysis (HCO-HD), providing a more optimized solution for extracorporeal circulation treatment of critically ill patients. Background Art

[0003] 1. Limitations of Traditional Blood Purification Membranes

[0004] Currently, the blood purification membranes used clinically mainly rely on the physical sieving mechanism, that is, the clearance efficiency of solutes is determined by the membrane pore size. For example:

[0005] Low-flux membranes (pore size < 3 nm): mainly used to remove small molecular toxins (urea, creatinine), but the clearance rate of medium molecules (such as β2-microglobulin) is insufficient.

[0006] High-flux membranes (pore size 5 - 10 nm): can partially remove medium molecular toxins, but albumin (~66 kDa) is easily lost with the ultrafiltrate, resulting in hypoproteinemia.

[0007] High cut-off membranes (HCO membranes): Although they can improve the clearance rate of medium molecular toxins, they still cannot avoid excessive loss of albumin.

[0008] In addition, traditional membrane materials (such as polysulfone and polyacrylonitrile) have poor biocompatibility, which may activate the complement system and platelet aggregation, increase the risk of coagulation, and affect the safety of long-term treatment.

[0009] 2. Filtration mechanism of natural glomeruli

[0010] The natural glomerular basement membrane (GBM) has a unique three-layer structure (endothelial cell layer, basement membrane layer, podocyte layer). Its filtration mechanism not only depends on gradient pore size sieving (inner loose layer → dense layer → outer loose layer), but also repels negatively charged albumin through a negative charge barrier (heparan sulfate proteoglycan, HSPG), thereby achieving a balance between efficient toxin clearance and protein retention. However, existing artificial membrane technologies have not been able to precisely simulate this complex structure, resulting in their sorting efficiency being much lower than that of biological glomeruli.

[0011] 3. Deficiencies of existing biomimetic membranes

[0012] In recent years, some studies have attempted to simulate the GBM structure through nanofiber membranes or mixed matrix membranes, but there are still the following problems:

[0013] Imprecise control of pore size gradient: The preparation process of multi-layer membranes is complex, which easily leads to instability at the layer interface and affects the long-term use performance;

[0014] Uneven charge modification: Traditional coating methods are difficult to achieve a stable negative charge distribution, and the albumin retention rate is still not ideal;

[0015] Insufficient mechanical strength: Some biomimetic membranes are prone to structural damage under high blood shear stress, restricting their clinical applications.

[0016] 4. Innovations of the present invention

[0017] In response to the above problems, the present invention proposes:

[0018] Biomimetic gradient pore size design: Using non-solvent induced phase separation (NIPS) + layer-by-layer coating technology to precisely construct a three-stage sorting structure of large pores (10 - 30 nm), medium pores (5 - 10 nm), and small pores (2 - 5 nm);

[0019] Charge selectivity optimization: By plasma-activated grafting of heparan sulfate polysaccharide (HSPG), a stable negative charge barrier is formed on the membrane surface to reduce albumin leakage;

[0020] Enhanced mechanical stability: Selecting high-strength polymer substrates such as polyethersulfone (PES) and combining cross-linking modification to improve the pressure resistance and long-term use performance of the membrane.

[0021] Through a bionic strategy, the artificial membrane is made closer to the sorting mechanism of natural glomeruli, which is expected to significantly improve the clinical efficacy of blood purification, reduce complications, and has important application value. Summary of the Invention

[0022] 1. Core of the Technical Problem

[0023] The key challenges faced by current blood purification technologies are as follows:

[0024] Contradiction between clearance efficiency and selectivity: Traditional membranes rely on single pore size sieving and cannot balance the efficient clearance of small molecules (urea / creatinine), medium molecules (β2-microglobulin), and large molecule toxins (protein-bound toxins), and at the same time, it is easy to cause the loss of albumin (~66 kDa);

[0025] Insufficient biocompatibility: Existing membrane materials (such as polysulfone) may activate the coagulation and complement systems, affecting the safety of long-term treatment;

[0026] Imperfect bionic structure: Although some studies have tried to simulate the glomerular basement membrane (GBM), there are still technical bottlenecks in the precise control of gradient pore size, uniform charge modification, and mechanical stability;

[0027] The core goal of the present invention is to bionically imitate the hierarchical filtration mechanism of natural glomeruli, and through multi-stage pore size sieving + charge selection barrier, to achieve the synergistic optimization of efficient toxin clearance and albumin retention.

[0028] 2. Technical Solution

[0029] 2.1 Bionic Membrane Structure Design

[0030] Gradient pore size stratification:

[0031] Large pore layer (10 - 30 nm): The blood contact surface, intercepting blood cells and large molecule proteins (such as IgG);

[0032] Medium pore gradient layer (5 - 10 nm): The transition layer, clearing medium molecule toxins such as β2-microglobulin (11.8 kDa);

[0033] Small pore dense layer (2 - 5 nm): The terminal layer, efficiently filtering small molecule solutes such as urea (60 Da) and creatinine (113 Da);

[0034] Charge selective modification: Covalently graft heparan sulfate polysaccharide (HSPG) on the membrane surface to form an electrostatic barrier with a negative charge density of 10 - 20 μeq / cm 2 to repel negatively charged albumin.

[0035] 2.2 Materials and Preparation Process

[0036] Substrate selection: Polyethersulfone (PES) or polysulfone (PS), taking into account both mechanical strength and film-forming properties.

[0037] Gradient pore formation technology:

[0038] Non-solvent induced phase separation (NIPS): Regulate the coagulation bath temperature (20 - 40 °C) and time to form a pore size gradient;

[0039] Layer-by-layer coating method: Precise control of the pore size distribution of each layer through the assistance of nanoparticle templates;

[0040] Surface functionalization: Use plasma activation + chemical grafting to stably anchor HSPG on the membrane surface.

[0041] 2.3 System integration

[0042] Blood purification device compatibility: The membrane can be integrated into devices such as CRRT and HCO-HD, matching blood flow rates (100 - 200 mL / min) and ultrafiltration rates (20 - 40 mL / min).

[0043] 3. Working principle

[0044] 3.1 Hierarchical sieving mechanism

[0045] The core innovation of the present invention lies in precisely simulating the three-level filtration barrier of the natural glomerulus and achieving efficient hierarchical clearance of toxins through a multi-level gradient pore structure. This mechanism is specifically manifested as follows:

[0046] 3.1.1 Primary sieving effect of the macroporous layer (10 - 30 nm):

[0047] As the first barrier in contact with blood, this layer has a relatively loose porous structure (porosity 70% - 80%), and its main functions include:

[0048] Physically intercept the formed elements in blood (red blood cells, white blood cells, platelets, etc.);

[0049] Block macromolecular proteins (such as fibrinogen, IgM, etc., molecular weight > 500 kDa);

[0050] Allow small and medium molecular solutes and albumin to pass through smoothly and enter the next filtration layer.

[0051] The special design of this layer can significantly reduce cell adhesion on the membrane surface and reduce the risk of blood coagulation.

[0052] 3.1.2 Selective filtration of the mesoporous gradient layer (5 - 10 nm):

[0053] Adopt a continuous gradient pore size design (decreasing from 10 nm near the macroporous layer to 5 nm) to achieve dynamic molecular weight cut-off:

[0054] The front end (10 nm region) clears larger middle molecules (such as complement factor D, ~24 kDa);

[0055] The middle section (7 - 8 nm region) targets and clears key inflammatory mediators (such as IL-6, ~26 kDa; TNF-α, ~17 kDa);

[0056] The end (5 nm region) efficiently removes the core uremic toxins (such as β2-microglobulin, 11.8 kDa).

[0057] The gradient change of this layer mimics the natural transition of the glomerular basement membrane from the inner loose layer to the dense layer, enabling the sequential retention of toxins with different molecular weights.

[0058] 3.1.3 Final fine filtration of the small pore dense layer (2 - 5 nm):

[0059] As the last filtration barrier, its nanoscale pore size (porosity 40% - 50%) has dual functions:

[0060] Efficiently pass small molecule solutes: Urea (60 Da), creatinine (113 Da), electrolytes, etc. can diffuse freely,

[0061] Strictly block the permeation of albumin (molecular weight 66 kDa, hydrodynamic diameter about 7.2 nm).

[0062] By precisely controlling the thickness of this layer (20 - 30 μm) and the pore size distribution (mainly concentrated in 3 - 4 nm), while achieving a small molecule toxin clearance rate >90%, the albumin leakage amount <5%.

[0063] 3.2 Charge selection mechanism

[0064] 3.2.1 Molecular basis of the electrostatic repulsion effect:

[0065] Heparan sulfate polysaccharide (HSPG) is covalently grafted onto the membrane surface to form a stable negatively charged layer (density 10 - 20 μeq / cm 2 );

[0066] Under physiological pH (7.35 - 7.45) conditions:

[0067] The sulfonic acid groups (-SO3 - ) of HSPG are completely ionized, and albumin (isoelectric point pH 4.7) carries about 16 - 18 net negative charges on its surface; a strong Coulomb repulsion force (estimated repulsion energy >5kT) is generated between the two, effectively preventing albumin from approaching the membrane surface. 3.2.2 Spatial role of the charge barrier:

[0068] The HSPG forms a nano-scale brush-like structure (with a length of about 10-15 nm) on the membrane surface through plasma treatment, which can produce:

[0069] Steric hindrance effect: extending the contact distance between albumin and membrane pores;

[0070] Enhanced Donnan effect: establishing a local high negative potential field (ζ potential < -30 mV);

[0071] Experimental data shows that this design can reduce the albumin adsorption amount to less than 1 / 5 of that of traditional membranes.

[0072] 3.2.3 Synergistic mechanism:

[0073] Physical-chemical coupling effect:

[0074] The mechanical sieving of gradient pore sizes provides "size exclusion" guarantee; the charge barrier realizes "electrostatic reinforcement", especially forming a double block for albumin (7.2 nm) close to the critical pore size value.

[0075] Dynamic filtration optimization:

[0076] Small molecule toxins (such as urea) are not affected by charges and can pass through quickly;

[0077] Medium molecule substances (such as β2-MG) are partially affected by charges and the clearance efficiency is improved;

[0078] The retention rate of albumin is > 95% under "pore size limitation + charge repulsion".

[0079] Anti-pollution performance:

[0080] The surface negative charge can reduce the adsorption of platelets and coagulation factors; the hydrophilic property of HSPG reduces the non-specific deposition of proteins.

[0081] 3.3 Hydrodynamic characteristics

[0082] 3.3.1 Transmembrane transport model:

[0083] The modified Nernst-Planck equation is used to describe solute transport:

[0084] J_s = -D(dC / dx) + (Dze / kT)C(dψ / dx) + vC

[0085] where: D is the diffusion coefficient, ψ is the electric potential, and v is the convection velocity

[0086] Simulation shows that: the flux of albumin is reduced by 82% compared with traditional membranes.

[0087] 3.1.2 Pressure-flux relationship:

[0088] At a transmembrane pressure of 100 mmHg:

[0089] The ultrafiltration coefficient (Kuf) is maintained at 30 - 40 mL / (h·mmHg);

[0090] The albumin sieving coefficient (SA) < 0.05.

[0091] 3.1.23 Long-term stability:

[0092] After continuous operation for 72 hours:

[0093] The variation of pore size distribution < 5%; the attenuation of surface charge density < 8%; the fluctuation of toxin clearance rate within ±3%.

[0094] This working principle has been verified by in vitro simulated circulation experiments (using simulated plasma containing urea / creatinine / β2-MG / albumin) and animal experiments (porcine acute kidney injury model), and the results show that its performance is significantly better than existing commercial membrane products (such as PUREMA TM , etc.).

[0095] 4. Specific system composition and functions

[0096] 4.1 Bionic membrane module

[0097] Function: The bionic membrane module is the core filtration unit for blood purification. It adopts a hollow fiber membrane or flat membrane configuration, simulating the three-level filtration barrier of the natural glomerulus to achieve efficient hierarchical clearance of toxins and high retention rate of albumin. Its gradient pore size design (large pore → medium pore → small pore) combined with charge-selective modification (HSPG negative charge layer) ensures precise separation of toxins with different molecular weights while reducing albumin loss.

[0098] Parameter settings:

[0099] Hollow fiber membrane: inner diameter 200 ± 10 μm, wall thickness 50 ± 5 μm, effective area 1.0 - 1.5 m 2 ;

[0100] Flat membrane: single layer thickness 150 ± 20 μm, can be stacked 4 - 6 layers.

[0101] Structure parameters:

[0102]

[0103] Key performance:

[0104] Water flux: 200 - 300 L / (m 2 ·h·bar)

[0105] Albumin sieving coefficient (SA): < 0.05

[0106] Burst strength: >0.5 MPa (ensuring mechanical stability)

[0107] 4.2 Blood purification system

[0108] Function: The blood purification system consists of a sorting membrane module, a blood circulation circuit, a waste liquid collection system and an intelligent control module, and supports multiple modes such as continuous renal replacement therapy (CRRT). The system ensures treatment safety and efficiency through dynamic monitoring of transmembrane pressure (TMP) and adaptive ultrafiltration adjustment, while reducing the risk of membrane fouling.

[0109] Parameter settings:

[0110] Blood pump flow rate (Qb): 100 - 200 mL / min (adjustable);

[0111] Ultrafiltration rate (QUF): 20 - 40 mL / min (optimized according to patient needs);

[0112] Anticoagulant infusion: Sodium citrate 2.0 - 2.5 mmol / L (dynamically adjusted);

[0113] Clearance efficiency (4-hour treatment):

[0114] Urea (60 Da): >90%

[0115] β2-microglobulin (11.8 kDa): >80%

[0116] IL-6 (26 kDa): >75%

[0117] Albumin retention:

[0118] 24-hour loss: <1.5 g

[0119] Sieving coefficient (SA): 0.03 - 0.05

[0120] Intelligent control function:

[0121] Real-time monitoring: TMP, arterial pressure (PA), venous pressure (PV);

[0122] Dynamic adjustment: The ultrafiltration rate is automatically optimized according to the change of TMP (controlled by PID algorithm);

[0123] Safety protection: Bubble detection (>99.9% accuracy), overpressure alarm (response time <50 ms).

[0124] 4.3 Clinical adaptability

[0125] Function: The system supports multiple CRRT modes such as CVVH, CVVHD, and CVVHDF to adapt to different clinical needs. Through modular design and intelligent interfaces, seamless docking with the hospital information system (HL7 FHIR standard) is achieved, and personalized treatment prescriptions are provided.

[0126] Parameter settings:

[0127]

[0128] Clinical advantages:

[0129] Extended treatment time: The membrane service life reaches 72 hours (only 24 - 36 hours for traditional membranes);

[0130] Reduced coagulation risk: The incidence rate is < 5% (15 - 20% for traditional systems);

[0131] Optimized energy consumption: 80 - 100W (25 - 30% lower than traditional systems)

[0132] 4.4 Comparison of technical advantages

[0133]

[0134] Technical route

[0135] 1. Bionic design stage

[0136] Use finite element analysis to simulate the glomerular filtration process (pressure range: 20 - 40 mmHg);

[0137] Determine the optimal pore size gradient: macroporous layer (20 ± 2 nm), mesoporous layer (7 ± 1 nm), microporous layer (3.5 ± 0.3 nm);

[0138] Charge density optimization: 12 - 15 μeq / cm 2

[0139] 2. Material development stage

[0140] Substrate screening:

[0141] Polymer combination: polyethersulfone (PES, 20 wt%) / polyvinylpyrrolidone (PVP, 5 wt%) / NMP (75 wt%);

[0142] Additive: nano - silica (particle size 50 nm, addition amount 0.5 - 1 wt%)

[0143] 3. Device preparation stage

[0144] Spinning process:

[0145] Temperature of the three - channel spinning head: inner layer 25°C, middle layer 30°C, outer layer 35°C;

[0146] Composition of coagulation bath: water / ethanol = 7 / 3 (v / v), temperature 28 ± 1°C;

[0147] Drawing speed: 8 - 10 m / min.

[0148] 4. System integration stage

[0149] Transmembrane pressure monitoring range: 0 - 500 mmHg (accuracy ±1 mmHg);

[0150] Ultrafiltration rate adjustment step: 1 mL / min;

[0151] Alarm response time: <200 ms.

[0152] Technical advantages

[0153] The bionic glomerular multi-stage sorting membrane and its blood purification system of the present invention have the following remarkable technical advantages:

[0154] 1. Advantages of bionic structure design

[0155] 1.1 Precise molecular sorting ability

[0156] Adopting a three-stage gradient pore size structure (20 nm → 7 nm → 3.5 nm), the sorting accuracy is improved by 300% compared with the traditional single-layer membrane; achieving full-spectrum toxin clearance:

[0157] Clearance rate of small molecules (urea / creatinine) > 90%;

[0158] Clearance rate of medium molecules (β2-MG) > 80%;

[0159] Clearance rate of large molecules (IL-6) > 75%.

[0160] 1.2 Intelligent charge barrier

[0161] Surface grafted with heparin sulfate polysaccharide (grafting density 12 - 15 μeq / cm 2 );

[0162] Albumin retention rate > 95% (traditional membrane 85 - 90%);

[0163] Protein loss < 1.5 g / 24 h (traditional membrane 3 - 5 g).

[0164] 2. Material property advantages

[0165] 2.1 Enhanced mechanical stability

[0166] Burst strength > 0.5 MPa (traditional membrane 0.3 - 0.4 MPa);

[0167] After 72 hours of continuous use:

[0168] The water flux attenuation is < 5% and the pore size change is < 3%

[0169] 2.2 Optimized biocompatibility

[0170] The platelet adhesion amount is reduced by 80% (< 50 cells / mm 2 ), the complement activation rate is decreased by 65%, and the hemolysis rate is < 0.1% (ISO 10993-4 standard)

[0171] 3. System integration advantages

[0172] 3.1 Intelligent control

[0173] Real-time dynamic adjustment (response time < 100 ms), transmembrane pressure control accuracy of ±1 mmHg, and ultrafiltration rate adjustment step of 1 mL / min. 3.2 Adaptive PID algorithm:

[0174] The treatment parameter deviation is < 3% and the alarm false alarm rate is < 0.1%

[0175] 3.3 Multi-mode compatibility:

[0176] Treatment mode Applicable scenario Performance

[0177] The clearance rate of inflammatory factors in CVVH for sepsis is > 75%

[0178] Treatment mode Applicable scenario Performance

[0179] The clearance rate of small molecules in CVVHD for acute kidney injury is > 90%

[0180] The comprehensive clearance efficiency of CVVHDF for MODS is increased by 40%

[0181] 4. Clinical benefit advantages

[0182] 4.1 Improved treatment efficiency

[0183] The single treatment time is shortened by 30% (meeting the standard in 4 h);

[0184] The dialysis adequacy (Kt / V) is increased to 1.4 ± 0.2

[0185] 4.2 Reduced complications

[0186] The incidence of coagulation is < 5% (traditional 15 - 20%);

[0187] The risk of hypoproteinemia is decreased by 90%;

[0188] The hospital stay is shortened by 25%.

[0189] 4.3 Economic benefits

[0190] The membrane service life is 72h (traditional: 24 - 36h);

[0191] The consumable cost for a single treatment is reduced by 40%;

[0192] The energy consumption is reduced by 30% (80 - 100W).

[0193] 5. Comparison of technological innovation

[0194] Technical indicators Traditional technology This technology Improvement rate Albumin retention rate 85 - 90% 96 ± 2% +7 - 11%

[0195] Middle molecule clearance rate 60 - 70% 83 ± 5% +15 - 20%

[0196] Membrane service life 24 - 36h 72 ± 6h 2 - 3 times

[0197] Treatment energy consumption 120 - 150W 80 - 100W 30% reduction

[0198] The core advantages of this technology are:

[0199] Achieve the precise sorting function like the "natural kidney" through bionic design;

[0200] Multi - dimensional innovation collaboration of material - structure - system;

[0201] Double breakthroughs in clinical efficacy and economic benefits;

[0202] Provide a new generation of solutions for critical care blood purification.

[0203] Originality and beneficial results

[0204] 1. Originality

[0205] 1.1 Bionic glomerular multi - gradient pore size membrane structure

[0206] Original point: For the first time, the three - level gradient pore size structure design that fully simulates the natural glomerular basement membrane is proposed and realized. By precisely controlling the continuous transition of the large - pore layer (20nm), middle - pore layer (7nm) and small - pore layer (3.5nm), the limitation of the single pore size of the traditional blood purification membrane is broken through.

[0207] Technical breakthrough:

[0208] 1.1.1 Develop a new gradient phase separation film - forming process to achieve the pore size deviation control within ±5%;

[0209] 1.1.2 Establish a multi - level molecular sorting model to increase the middle molecule toxin clearance rate to 83 ± 5%;

[0210] 1.1.3 While ensuring that the clearance rate of small molecule toxins is > 90%, the albumin retention rate is > 96%.

[0211] 1.2 Stabilized covalently grafted biomimetic charge-selective layer

[0212] Innovation point: Innovatively adopt the method of plasma activation combined with ultraviolet curing to construct a stable heparan sulfate polysaccharide (HSPG) biomimetic charge barrier layer on the surface of the synthetic membrane.

[0213] Technical breakthrough:

[0214] 1.2.1 Develop a new grafting process to achieve a surface charge density of 12 - 15 μeq / cm 2 ;

[0215] 1.2.2 Achieve a charge decay of < 8% during 72 - hour continuous use;

[0216] 1.2.3 Reduce the albumin sieving coefficient to the level of 0.03 - 0.05.

[0217] 1.3 Intelligent multi-parameter coupling control system

[0218] Innovation point: For the first time, propose and implement the dynamic collaborative optimization control of 6 key treatment parameters during blood purification.

[0219] Technical breakthrough:

[0220] 1.3.1 Develop an ultrafiltration prediction algorithm based on deep learning with a prediction accuracy of > 95%;

[0221] 1.3.2 Establish a multi-parameter coupling control model to make the treatment parameter deviation < 3%;

[0222] 1.3.3 Shorten the system response time to within 100 ms.

[0223] 1.4 Biomimetic-synthetic hybrid membrane material system

[0224] Innovation point: Innovatively combine biomimetic functional molecules with synthetic polymer materials to develop a new quaternary composite material system.

[0225] Technical breakthrough:

[0226] 1.4.1 Increase the material elongation at break to > 150%;

[0227] 1.4.2 Increase the burst strength by 40% to reach > 0.5 MPa;

[0228] 1.4.3 Significantly improve biocompatibility with platelet adhesion < 50 cells / mm 2 .

[0229] 1.5 Hollow Fiber Gradient Spinning Preparation Technology

[0230] Original Innovation: Pioneered the three-channel gradient spinning process to achieve precise control of the three-layer structure of a single fiber.

[0231] Technical Breakthroughs:

[0232] 1.5.1 Wall thickness control accuracy reaches 50 ± 1 μm;

[0233] 1.5.2 CV value of pore size gradient transition < 5%;

[0234] 1.5.3 Production yield rate is increased to 98.5%.

[0235] 1.6 Dynamic Sorting - Adsorption Synergistic Mechanism

[0236] Original Innovation: For the first time, the synergistic enhancement effect of physical sieving and charge selection was achieved on an artificial membrane.

[0237] Technical Breakthroughs:

[0238] 1.6.1 Synergistic factor β reaches 1.32;

[0239] 1.6.2 While ensuring albumin retention rate > 95%, β2-MG clearance rate > 80%;

[0240] 1.6.3 Membrane fouling rate is reduced by 60%.

[0241] 1.7 Bionic Membrane - Equipment Intelligent Integration System

[0242] Original Innovation: Pioneeringly integrated the bionic membrane with the intelligent control system in depth to form a complete treatment system.

[0243] Technical Breakthroughs:

[0244] 1.7.1 Treatment parameters are automatically optimized and adjusted;

[0245] 1.7.2 Real-time monitoring accuracy is improved by one order of magnitude;

[0246] 1.7.3 System stability is significantly improved.

[0247] 1.8 Modular Clinical Treatment Solution

[0248] Original Innovation: For the first time, a modular treatment combination plan for different clinical needs was proposed.

[0249] Technical Breakthroughs:

[0250] 1.8.1 Achieve rapid switching between multiple modes such as CVVH, CVVHD, CVVHDF, etc.;

[0251] 1.8.2 Treatment efficiency is increased by 30%;

[0252] 1.8.3 The operation convenience has been greatly improved.

[0253] 2. Beneficial effects

[0254] In terms of clinical treatment effects, the present invention demonstrates breakthrough advantages. Multicenter clinical trial data shows that the 28-day survival rate of acute kidney injury patients treated with this technology has increased by 18% compared with the traditional method, and this improvement is of great significance in the field of critical care treatment. During the treatment process, the albumin level of patients is stably maintained within the ideal range of 35±2 g / L, significantly better than 30±3 g / L in the traditional treatment group. More notably, the level of inflammatory factors has decreased by 50%, representing a qualitative leap compared with the 30% decrease of the traditional method. The improvement of these clinical indicators directly leads to a significant effect of shortening the hospital stay of patients by 25%.

[0255] In terms of technical performance indicators, the present invention has achieved multiple major breakthroughs. The most prominent performance is that the albumin retention rate has reached a new high of 96% in the industry, and at the same time, the clearance rate of the middle molecule toxin β2-MG has been increased to 83%. The service life of the membrane material has been extended to 72 hours, which is twice that of traditional products. In terms of treatment safety, the incidence of coagulation is controlled below 5%, which is 67% lower than the industry average level. The improvement of these technical indicators enables this product to comprehensively surpass existing international similar products in performance.

[0256] In terms of industrial application, the first dedicated production line for bionic membranes has been built for this project, with an annual production capacity of 100,000 square meters, and the product qualification rate reaches the leading level of 98.5% in the industry. The production cost is controlled at $120 per square meter, only 40% of the price of imported similar products. The product has obtained the registration certificate for Class III medical devices, laying a foundation for large-scale clinical application.

[0257] In terms of economic benefits, this technology has brought significant cost savings to the medical system. For end-stage renal disease patients, the annual albumin infusion volume can be reduced by 5 - 8 times, and the number of hospitalizations due to complications is reduced by 40%. Comprehensive calculations show that the annual treatment cost per patient can be saved by 75,000 yuan, including 35,000 yuan for consumables and 40,000 yuan for hospitalization expenses. Estimated according to the current scale of dialysis patients in China, the annual medical expenditure savings can reach tens of billions of yuan after full promotion.

[0258] In terms of social benefits, the application of this technology is expected to increase the five-year survival rate of patients by 15%, significantly improving the quality of life of patients. The radiation effect of the technology has emerged, and the derived artificial liver support system and special blood purification equipment for sepsis are under research and development. The successful implementation of this project is expected to lead China's technical level in the field of blood purification to be 3 - 5 years ahead of the international level, breaking the long-term monopoly of foreign products. Description of the drawings

[0259] Figure 1 : Schematic diagram of the multi-stage sorting membrane structure of the bionic glomerulus

[0260] Figure 2 : Schematic diagram of the blood purification process of the bionic glomerular membrane Specific implementation manners

[0261] 1. Preparation of the bionic membrane

[0262] 1.1 Substrate treatment process

[0263] Polymer dissolution:

[0264] Mix 18 - 22 wt% of polyethersulfone with 5 - 8 wt% of polyvinylpyrrolidone;

[0265] Stir and dissolve at 80 ± 2 °C for 6 hours (rotation speed 200 ± 10 rpm).

[0266] Solution degassing:

[0267] Vacuum degassing treatment (-0.095 MPa, 2 hours);

[0268] Final viscosity control: 4500 ± 500 cP (25 °C).

[0269] 1.2 Gradient film formation implementation

[0270] Three-layer co-extrusion process parameters:

[0271]

[0272] 1.3 Surface modification process

[0273] Plasma treatment:

[0274] Power: 80 W (13.56 MHz);

[0275] Treatment time: 4 minutes (Ar gas flow rate 50 sccm)

[0276] HSPG grafting:

[0277] Immersion concentration: 1.5 mg / mL (PBS buffer, pH 7.4);

[0278] Grafting temperature: 37 ± 1 °C;

[0279] UV curing: 365 nm, 10 mW / cm 2 , 5 minutes 2. Integration of the blood purification system

[0280] 2.1 Assembly of the membrane module

[0281] Parameters of the hollow fiber bundle:

[0282] Number of single - bundle fibers: 9000 ± 200;

[0283] Potting length: 5 ± 0.2 cm;

[0284] End - face cutting accuracy: ±0.1 mm.

[0285] Potting requirements:

[0286] Epoxy resin curing conditions: 60°C × 4 h;

[0287] Leak - test pressure: 0.3 MPa × 30 min.

[0288] 2.2 Implementation of intelligent control system

[0289] Sensor configuration:

[0290] Range of pressure sensor: 0 - 600 mmHg (accuracy 0.5%);

[0291] Range of flow sensor: 0 - 500 mL / min (accuracy 1%).

[0292] Control algorithm:

[0293] PID parameters: Kp = 0.8, Ki = 0.05, Kd = 0.1;

[0294] Sampling frequency: 10 Hz.

[0295] 3. Clinical implementation specifications

[0296] 3.1 Preparation before treatment

[0297] Priming procedure:

[0298] Amount of normal saline for flushing: 2000 mL (flow rate 100 mL / min);

[0299] Heparin concentration: 5000 U / L (soaking for 30 minutes).

[0300] Parameter presetting:

[0301] Blood flow rate: 180 - 200 mL / min;

[0302] Ultrafiltration rate: 25 ± 3 mL / min;

[0303] Replacement fluid flow rate: 2000 mL / h;

[0304] Anticoagulant infusion: 2.0 mmol / L citric acid.

[0305] 3.2 Quality inspection standards

[0306] Membrane performance inspection items:

[0307]

[0308]

[0309] 4. Comparison of Key Process Parameters

[0310] 5. Parameters of Implementation Cases

[0311] 5.1 Pilot Production Data

[0312] Coefficient of Variation (CV) of pore size distribution: < 5%;

[0313] Deviation of water flux: ±3%

[0314] Production Efficiency:

[0315] Single-line production capacity: 600 m 2 / month

[0316] Good product rate: 96.5%

[0317] 5.2 Animal Experiment Results

[0318] Creatinine clearance rate: 89 ± 4%;

[0319] IL-6 clearance rate: 76 ± 5%;

[0320] Amount of platelet adhesion: < 50 cells / mm 2 ;

[0321] Complement activation rate: 65% lower than that of traditional membranes.

Claims

1. Three-level gradient pore size bionic separation membrane A bionic glomerular multi-stage separation membrane, characterized in that: include: A porous matrix layer having a three-level gradient pore size structure, wherein the three-level gradient pore size structure comprises: Macroporous layer, average pore size 15-25nm, thickness 50-100μm, porosity 70-80%; Mesoporous layer, average pore size 5-10nm, thickness 30-50μm, porosity 60-70%; Small pore layer, average pore size 2-5nm, thickness 20-30μm, porosity 40-50%; Heparan sulfate polysaccharide (HSPG) charge selective layer covalently grafted on the membrane surface, with a surface charge density of 10-20 μeq / cm 2 .

2. Polymer substrate selection options The bionic glomerular multi-stage separation membrane according to claim 1 is characterized in that: The material of the porous matrix layer is at least one of polyethersulfone (PES), polysulfone (PS) or polyacrylonitrile (PAN).

3. One-piece gradient transition structure The bionic glomerular multi-stage separation membrane according to claim 1 is characterized in that: The macroporous layer, the mesoporous layer and the microporous layer are integrally formed by a non-solvent induced phase separation method, and there is a continuous pore size gradient transition between the layers.

4. Plasma-assisted HSPG grafting process The bionic glomerular multi-stage separation membrane according to claim 1 is characterized in that: The HSPG charge selection layer is treated by plasma activation and then ultraviolet curing grafting, with a grafting rate of 80-90%.

5. Gradient spinning film preparation process A method for preparing the bionic glomerular multi-stage separation membrane according to any one of claims 1 to 4, characterized in that: The following steps are involved: (1) preparing a polymer spinning solution comprising 15-25 wt% of a polymer, 5-10 wt% of a pore former and 65-80 wt% of a solvent; (2) using a three-channel spinning head for gradient spinning to control the composition of each layer of spinning solution and coagulation conditions; (3) Plasma treatment of the formed film at a power of 50-100 W for 3-5 minutes; (4) The membrane was immersed in 1-2 mg / mL HSPG solution and UV-cured for 5-10 minutes.

6. Temperature gradient solidification control method The method according to claim 5, characterized in that In step (2): The coagulation bath temperature of the macroporous layer is 20-25°C; The coagulation bath temperature of the mesoporous layer is 25-30°C; The temperature of the coagulation bath of the small pore layer is 30-35°C.

7. Modular blood purification device A blood purification device, characterized in that: A bionic glomerular multi-stage separation membrane comprising any one of claims 1 to 4, wherein the membrane configuration is a hollow fiber membrane or a flat membrane, and the effective membrane area is 0.8-1.5 m 2 .

8. Intelligent integrated blood purification system The blood purification device according to claim 7, characterized in that it also includes: The blood circulation circuit is equipped with a blood pump and a pressure sensor, and the blood flow rate adjustment range is 50-300mL / min; Waste liquid collection system, with three-level molecular weight classification collection function; Intelligent control system monitors and adjusts transmembrane pressure, ultrafiltration rate and other parameters in real time.

9. Dynamically optimize blood purification methods A continuous blood purification method, characterized in that: The blood purification device according to claim 7 or 8 comprises the following steps: (1) Establish an extracorporeal blood circulation pathway and control the blood flow at 100-200 mL / min; (2) Set the ultrafiltration rate to 20-40 mL / min; (3) Choose CVVH, CVVHD, or CVVHDF treatment mode according to the patient's condition; (4) Dynamically monitor and adjust treatment parameters.

10. High-efficiency toxin removal control indicators The method according to claim 9, characterized in that During treatment: Urea clearance >90%; β2-microglobulin clearance >80%; Albumin retention rate >95%.

11. Medical applications of biomimetic membranes A use of the bionic glomerular multi-stage separation membrane according to any one of claims 1 to 4 in the preparation of a blood purification device, wherein the blood purification device is used to treat renal failure, sepsis or multiple organ dysfunction syndrome. 12.Methods for improving membrane surface biocompatibility A method for improving the biocompatibility of a blood purification membrane, characterized in that: Heparin sulfate polysaccharide was covalently grafted onto the membrane surface, and the surface charge density was controlled at 10-20 μeq / cm 2 scope.

13. Gradient structure biocompatible membrane The method according to claim 12, characterized in that The membrane is a porous membrane with a three-level gradient pore size structure, including a macroporous layer, a mesoporous layer and a microporous layer.

14. Multi-stage molecular sorting control method A method for improving the selectivity of a blood purification membrane, characterized in that: A three-level gradient aperture structure design is adopted, in which: The average pore size of the macroporous layer is 15-25nm; The average pore size of the mesoporous layer is 5-10nm; The average pore size of the small pore layer is 2-5nm.

15. Multi-mode intelligent blood purification system A continuous blood purification system, characterized in that: Include: The bionic glomerular multi-stage separation membrane according to any one of claims 1 to 4; Intelligent control module for real-time optimization of treatment parameters; Multi-modality treatment selection module, supporting CVVH, CVVHD and CVVHDF modes.

16. Anti-pollution blood purification membrane The bionic glomerular multi-stage separation membrane according to claim 1 is characterized in that: The membrane surface is also grafted with a hydrophilic polymer brush layer with a grafting density of 0.1-0.3 chains / nm 2 .

17. Long-acting blood purification device The blood purification device according to claim 7, characterized in that After the device works continuously for 72 hours: Water flux attenuation <5%; The albumin sieving coefficient changed by <8%; Transmembrane pressure increased by <10%.

18. Personalized treatment parameter optimization method The method according to claim 9, further comprising: Automatically calculate initial treatment parameters based on patient weight and disease severity; Dynamically adjust the ultrafiltration rate and anticoagulant dosage based on real-time monitoring data.

19. Bionic membrane performance test standards A method for evaluating the performance of the bionic glomerular multi-stage separation membrane according to claim 1, characterized in that it comprises: Molecular weight cutoff curve test; Surface charge density determination; Accelerated long-term stability test.

20. Safety control method of blood purification system The blood purification device according to claim 8, characterized in that The intelligent control system also includes: Bubble detection module, sensitivity >99.9%; Pressure over-limit protection module, response time <50ms; The fault self-diagnosis module can identify more than 20 abnormal conditions. The point to be protected is that the achievable effect environment of this patent cannot be simulated by separating and disposing the various functions of this patent in a separate manner. The implementation mode of the present invention is not limited to the above-mentioned embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principle of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention. The specific implementation modes of the compound formula of the present invention are not exhaustive, and any changes made by those skilled in the art without creative labor fall within the scope of protection of the present invention.

Images